NEWARK, NJ - June 18, 2025 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced the continuation of its subsidiary Cyclo Therapeutics' 96-week pivotal phase 3 TransportNPC study. This study evaluates the intravenous (IV) Trappsol® Cyclo™ for the potential treatment of Niemann-Pick Disease Type C1 (NPC1). The decision to proceed was based on the independent Data Monitoring Committee's $(DMC.AU)$ review of safety and efficacy data at the prespecified 48-week interim analysis. The FDA has accepted the statistical analysis plan for the study, indicating progress in the clinical development phase. The study aims to explore the potential of Trappsol® Cyclo™ as a treatment option in addressing the root cause of NPC1. The continuation to 96 weeks reflects the ongoing commitment to assessing the investigational candidate's systemic and neurological treatment potential. Results of the interim analysis have been presented, and further results will be available upon completion of the study.